News | Cardiovascular Clinical Studies | February 18, 2026

HeartX Cardiovascular Accelerator Seeks Applications for 2026

The HeartX program, is a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market.

MedAxiom, HTA, accelerator

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused healthcare accelerator that facilitates guaranteed hospital pilot projects and clinical trials for accomplished, early-stage companies bringing new cardiovascular innovations to market.

Applications for the 2026 HeartX cohort will be accepted until April 30, 2026, and selected companies will be announced in September 2026. The program is seeking companies in three categories: digital health and software, medical devices and diagnostic platforms. Each selected company will receive $150,000 in investment capital and is guaranteed at least one pilot project or clinical study with cardiology practices in Arkansas and nationwide.

"The HeartX program continues to focus on what early-stage cardiovascular companies need most: meaningful access to providers and real-world clinical validation," said Jeff Stinson, director of HTA. "By guaranteeing pilot projects and clinical studies with leading cardiology practices, we help companies move faster, generate credible data, and accelerate their path to market. We're excited to open applications for the 2026 cohort and to continue our strong partnership with MedAxiom."

"HeartX is designed to remove the biggest barriers facing early-stage cardiovascular innovators — access, validation, and scale," said Joe Sasson, PhD, MedAxiom's chief commercial officer and executive vice president of Ventures. "Through HeartX, companies gain not only capital, but direct engagement with leading cardiovascular programs that are actively seeking solutions to improve care delivery. We're excited to see the next generation of innovators bring forward ideas that will shape the future of cardiovascular care, and we encourage visionary companies around the world to apply."

HTA is in its ninth year of administering accelerator programs focused exclusively on provider engagement with early-stage companies and is entering its fifth year of partnership with MedAxiom to deliver HeartX as a premier cardiovascular accelerator.

More information about the program and the application process is available at HeartXaccelerator.com.


Related Content

News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
Subscribe Now